Apimeds Pharmaceuticals US (APUS): רווחיות מכירות לפי רווח נקי

סמל ולוגו של המותג Apimeds Pharmaceuticals US (APUS)

Apimeds Pharmaceuticals (APUS) develops innovative treatments for arthritis and multiple sclerosis based on bee venom. The core operating net margin illustrates the effect of this diversification, with the -1053.70 value serving as the baseline indicator. The business is shielded from geopolitics through strict compliance with Western medical regulations. However, a narrow therapeutic profile and raw material standardization challenges create significant competitive pressure.

Apimeds Pharmaceuticals US (APUS) - שולי רווח נקי ממכירות מ-10.05.2025 עד 19.11.2026

פילוחי נתונים אנליטיים מרוכזים עבור Apimeds Pharmaceuticals US (APUS)

- נתוני שווי שוק בבורסה:
ניתוח בסיסי של החברה:Apimeds Pharmaceuticals, Inc. - APUS
סחורת הדגל של apimedsus.com

Net profit margin measures the portion of profit remaining after all operating and financial expenses are deducted from revenue. This metric reflects the final efficiency of converting revenue into actual capital. The monopoly position of Apimeds Pharmaceuticals (APUS) in bee venom therapy allows the company to maintain high markups on its drugs. This directly supports a positive trend in the sales margin ratio. The dynamics of this indicator serve as an objective measure of asset management quality.